Abstract
Aripiprazole was the first antipsychotic developed to possess agonist properties at dopamine D(2) autoreceptors, a groundbreaking strategy that presented a new vista for schizophrenia drug discovery. The dopamine D(2) receptor is the crucial target of all extant antipsychotics, and all developed prior to aripiprazole were D(2) receptor antagonists. Extensive blockade of these receptors, however, typically produces extrapyramidal (movement) side effects, which plagued first-generation antipsychotics, such as haloperidol. Second-generation antipsychotics, such as clozapine, with unique polypharmacology and D(2) receptor binding kinetics, have significantly lower risk of movement side effects but can cause myriad additional ones, such as severe weight gain and metabolic dysfunction. Aripiprazole's polypharmacology, characterized by its unique agonist activity at dopamine D(2) and D(3) and serotonin 5-HT(1A) receptors, as well as antagonist activity at serotonin 5-HT(2A) receptors, translates to successful reduction of positive, negative, and cognitive symptoms of schizophrenia, while also mitigating risk of weight gain and movement side effects. New observations, however, link aripiprazole to compulsive behaviors in a small group of patients, an unusual side effect for antipsychotics. In this review, we discuss the chemical synthesis, pharmacology, pharmacogenomics, drug metabolism, and adverse events of aripiprazole, and we present a current understanding of aripiprazole's neurotherapeutic mechanisms, as well as the history and importance of aripiprazole to neuroscience.